Gene therapies, CAR-T immunotherapies and solid-organ transplants used to be the preserve of tertiary centres. That is still where the treatments happen, but the aftercare increasingly lands on the high street. A patient who received Casgevy at a specialist centre in Manchester may pick up their next co-trimoxazole prescription in Rochdale. A child who completed tisagenlecleucel at Great Ormond Street will collect aciclovir from a local branch for at least a year.
Community pharmacists are rarely briefed on these handovers. Discharge letters are long, written for GPs, and often arrive weeks after the first community prescription. This piece sets out a structured framework pharmacists can use at the counter — not a substitute for the shared-care protocol, but a practical checklist for the five minutes between prescription arrival and patient collection.
Why the handover matters
Most specialist-therapy regimens depend on three prophylactic pillars:
- Aciclovir or valaciclovir — to prevent herpesvirus reactivation after lymphodepletion or immunosuppression. Typically continued for six to twelve months post-infusion.
- Co-trimoxazole — to prevent Pneumocystis jirovecii pneumonia in patients with low CD4 counts or ongoing immunosuppression. Dose and duration vary by centre.
- Immunoglobulin replacement — for hypogammaglobulinaemia following B-cell–depleting therapies. Usually a hospital-administered infusion, but community pharmacy sees the associated prescriptions for antibacterial and antifungal cover.
A missed dose of any of these in the early window can have serious consequences. The community pharmacist is often the last professional to see the patient before an interruption.
The framework: five questions to ask at the counter
1. What therapy, when, where. Confirm the specialist therapy by name and the approximate month of infusion. "CAR-T last November" is enough to anchor the timeline. If the patient cannot answer, ask for the discharge letter or the clinical nurse specialist's number.
2. What are you currently taking. Reconcile against the prescription in hand. Look for the three prophylactic pillars above plus any targeted prophylaxis (letermovir for CMV risk, posaconazole for fungal prophylaxis in haematology patients).
3. When do you next see the specialist team. If the answer is more than six weeks away or "I'm not sure", flag that back through the GP. Specialist-therapy patients should have a named contact at the tertiary centre.
4. Any new symptoms. Fever, breathlessness, rash, mouth ulcers, unexplained bruising — all red flags in the immunosuppressed post-specialist-therapy patient. The pharmacy is a low-threshold place to raise these.
5. Do you have an alert card. Many specialist-therapy patients carry a wallet card listing the centre, the therapy, the date, and an emergency contact. Photograph or note this in the patient medication record.
Red flags that warrant same-day escalation
| Symptom | Why it matters |
|---|---|
| Temperature ≥38°C | Neutropenic sepsis risk — attend A&E, alert treating centre |
| New breathlessness or dry cough | Possible PJP, CMV pneumonitis or graft-versus-host lung |
| Unusual bruising or petechiae | Cytopenia, possible late graft failure |
| Rash with mucosal involvement | Possible GvHD, drug reaction |
| Confusion or seizure | ICANS (in CAR-T patients, can occur weeks post-infusion) |
These are not conditions for Pharmacy First consultation. The appropriate route is a same-day call to the treating centre's on-call haematologist or, where access is unclear, A&E with the alert card.
Prescription issues worth a phone call
- Antiviral dose change. Aciclovir doses post-transplant (often 800mg four times daily) can look like prescribing errors to a dispenser used to shingles doses. Confirm with the prescriber before querying the patient.
- Co-trimoxazole substitution. If co-trimoxazole is unavailable, do not substitute alternative antibiotics without discussing with the specialist team — pentamidine, dapsone and atovaquone each have different monitoring needs.
- Live-vaccine timing. Post–CAR-T and post–gene-therapy patients should not receive live vaccines for at least 12 months, sometimes longer. If a seasonal flu clinic prescription crosses the counter, pause and confirm.
- Concomitant immunosuppression. Calcineurin inhibitors (ciclosporin, tacrolimus) have narrow therapeutic windows. Any new antibiotic, antifungal or even St John's Wort can shift levels; flag these interactions proactively.
Why this matters for the sector
The UK Rare Diseases Action Plan 2026 makes clear that more gene, cell and advanced-therapy medicines will enter NHS use each year. The community pharmacy network is part of the long-tail safety structure that makes this expansion deliverable. Pharmacists who build a consistent, calm intake framework will catch problems earlier and protect both the patient and the specialist commissioning pathway.
A structured five-question check takes less time than reading a discharge summary and is more useful at the point of dispensing. It is a small change in practice that matches the scale of change in the medicines being dispensed.
Further reading on PharmSee
- Pharmacist workforce dashboard: /salary
- Live pharmacy vacancies by region: /app/jobs
- Pharmacy locator: /app/pharmacies
Caveats
This framework is a practical aide for community pharmacists and does not replace the shared-care protocol or discharge summary from the treating centre. Drug doses quoted are illustrative — always follow the prescription and specialist-centre guidance. Pharmacists with uncertainty should contact the patient's named clinical nurse specialist or treating consultant.
Sources
- NICE, Highly Specialised Technologies guidance, published programme page (2026).
- NHS England, Specialised Services commissioning framework (2026).
- Department of Health and Social Care, UK Rare Diseases Action Plan 2026, 14 April 2026.